{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:21:06Z","timestamp":1785165666413,"version":"3.55.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>This study aimed to evaluate the adverse event profile of remimazolam, a novel ultra-short-acting benzodiazepine, with a focus on its safety in the respiratory, cardiovascular, and immune systems across diverse patient populations. We analyzed adverse event reports from the FAERS database over a defined period, performing signal detection using the proportional reporting ratio (PRR) and the reporting odds ratio (ROR), and contextualized the findings with a concurrent literature review. Remimazolam demonstrated a strong signal for hypoventilation. In the cardiovascular system, it was associated with serious adverse events, including cardiac and cardiorespiratory arrest, particularly in high-risk patients. Furthermore, we detected significant signals for severe hypersensitivity reactions, such as anaphylactic shock and laryngeal edema, while signals in other systems were less pronounced but remained clinically significant. Given that the study population was predominantly elderly, and considering the serious nature of the identified signals, its potential for adverse events necessitates vigilant monitoring. Future research should focus on clarifying risks within specific high-risk groups to establish optimized safety protocols.<\/jats:p>","DOI":"10.1371\/journal.pone.0330769","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T17:24:52Z","timestamp":1755883492000},"page":"e0330769","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Remimazolam\u2019s clinical application and safety: A signal detection analysis based on FAERS data and literature support"],"prefix":"10.1371","volume":"20","author":[{"given":"Gang","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9922-0938","authenticated-orcid":true,"given":"Qingbo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"6","key":"pone.0330769.ref001","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40265-020-01299-8","article-title":"Remimazolam: First Approval","volume":"80","author":"SJ Keam","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"pone.0330769.ref002","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1186\/s13063-022-06935-0","article-title":"Efficacy and safety of remimazolam tosylate for sedation during upper gastrointestinal endoscopy: study protocol for a multicenter randomized controlled trial","volume":"23","author":"H Zhu","year":"2022","journal-title":"Trials"},{"key":"pone.0330769.ref003","doi-asserted-by":"crossref","first-page":"690875","DOI":"10.3389\/fphar.2021.690875","article-title":"Remimazolam: Non-Clinical and Clinical Profile of a New Sedative\/Anesthetic Agent","volume":"12","author":"GJ Kilpatrick","year":"2021","journal-title":"Front Pharmacol"},{"key":"pone.0330769.ref004","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.2147\/DDDT.S474854","article-title":"Remimazolam in General Anesthesia: A Comprehensive Review of Its Applications and Clinical Efficacy","volume":"18","author":"H Zhang","year":"2024","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"pone.0330769.ref005","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s40001-023-01440-9","article-title":"Remimazolam tosylate\u2019s long-term sedative properties in ICU patients on mechanical ventilation: effectiveness and safety","volume":"28","author":"Z Yao","year":"2023","journal-title":"Eur J Med Res"},{"issue":"4","key":"pone.0330769.ref006","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Y Wang","year":"2024","journal-title":"Andrology"},{"key":"pone.0330769.ref007","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"B Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0330769.ref008","article-title":"Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study","volume":"379","author":"MM Dhodapkar","year":"2022","journal-title":"BMJ"},{"issue":"10","key":"pone.0330769.ref009","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach","volume":"46","author":"V Giunchi","year":"2023","journal-title":"Drug Saf"},{"issue":"4","key":"pone.0330769.ref010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"H Yang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"pone.0330769.ref011","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"B Zhao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"pone.0330769.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/5132916","article-title":"Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment","volume":"2024","author":"J Li","year":"2024","journal-title":"Int J Clin Pract"},{"issue":"11","key":"pone.0330769.ref013","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine","volume":"23","author":"C Zhong","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"pone.0330769.ref014","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1038\/s41598-024-57909-y","article-title":"Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database","volume":"14","author":"F Huang","year":"2024","journal-title":"Sci Rep"},{"key":"pone.0330769.ref015","doi-asserted-by":"crossref","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Y Pan","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0330769.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300268","article-title":"A simulation-based comparison of drug-drug interaction signal detection methods","volume":"19","author":"D Jung","year":"2024","journal-title":"PLoS ONE"},{"issue":"3","key":"pone.0330769.ref017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","article-title":"Quantitative methods in pharmacovigilance: focus on signal detection","volume":"26","author":"M Hauben","year":"2003","journal-title":"Drug Saf"},{"issue":"24","key":"pone.0330769.ref018","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1093\/bioinformatics\/btaa1009","article-title":"glmGamPoi: fitting Gamma-Poisson generalized linear models on single cell count data","volume":"36","author":"C Ahlmann-Eltze","year":"2020","journal-title":"Bioinformatics"},{"issue":"12","key":"pone.0330769.ref019","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40264-015-0345-1","article-title":"Statistical Signal Detection as a Routine Pharmacovigilance Practice: Effects of Periodicity and Resignalling Criteria on Quality and Workload","volume":"38","author":"M Lerch","year":"2015","journal-title":"Drug Saf"},{"issue":"10","key":"pone.0330769.ref020","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40265-021-01544-8","article-title":"Remimazolam: A Review in Procedural Sedation","volume":"81","author":"A Lee","year":"2021","journal-title":"Drugs"},{"key":"pone.0330769.ref021","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.2147\/DDDT.S384155","article-title":"Remimazolam: An Updated Review of a New Sedative and Anaesthetic","volume":"16","author":"Q Hu","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"pone.0330769.ref022","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s13054-023-04760-8","article-title":"Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study","volume":"27","author":"Y Tang","year":"2023","journal-title":"Crit Care"},{"issue":"10","key":"pone.0330769.ref023","doi-asserted-by":"crossref","first-page":"495","DOI":"10.14740\/jmc4013","article-title":"Remimazolam for Sedation During Upper Gastrointestinal Endoscopy in an Adolescent","volume":"13","author":"A Garrett","year":"2022","journal-title":"J Med Cases"},{"issue":"32","key":"pone.0330769.ref024","article-title":"Can remimazolam be safely used in cardiac tamponade?: A case report","volume":"102","author":"HJ Heo","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"pone.0330769.ref025","doi-asserted-by":"crossref","first-page":"938940","DOI":"10.3389\/fmed.2022.938940","article-title":"The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial","volume":"9","author":"Y Qiu","year":"2022","journal-title":"Front Med"},{"issue":"12","key":"pone.0330769.ref026","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3390\/medicina59122136","article-title":"Remimazolam-Based Anesthesia in Patients with Heart Failure Due to Mitral Regurgitation and Low Left Ventricular Function: A Case Series","volume":"59","author":"A Kitaura","year":"2023","journal-title":"Medicina"},{"issue":"3","key":"pone.0330769.ref027","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2334\/josnusd.21-0051","article-title":"Sedation outcomes for remimazolam, a new benzodiazepine","volume":"63","author":"S Oka","year":"2021","journal-title":"J Oral Sci"},{"issue":"11","key":"pone.0330769.ref028","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/EJA.0000000000001902","article-title":"Remimazolam and serious adverse events: A scoping review","volume":"40","author":"S Kempenaers","year":"2023","journal-title":"Eur J Anaesthesiol"},{"issue":"1","key":"pone.0330769.ref029","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cpdd.797","article-title":"Effects of Vitamin D Receptor, Cytochrome P450 3A, and Cytochrome P450 Oxidoreductase Genetic Polymorphisms on the Pharmacokinetics of Remimazolam in Healthy Chinese Volunteers","volume":"10","author":"K Hu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"pone.0330769.ref030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40981-021-00474-4","article-title":"Anesthetic management of super-elderly patients with remimazolam: a report of two cases","volume":"7","author":"J Nakayama","year":"2021","journal-title":"JA Clin Rep"},{"key":"pone.0330769.ref031","article-title":"Comparison of Remimazolam and Propofol on Postoperative Delirium in Elderly Patients Undergoing Radical Resection of Colon Cancer: A Single-Center Prospective Randomized Controlled Study","volume":"30","author":"T Liu","year":"2024","journal-title":"Med Sci Monit"},{"issue":"1","key":"pone.0330769.ref032","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s12871-023-02249-z","article-title":"Effects of remimazolam combined with sufentanil on hemodynamics during anesthetic induction in elderly patients with mild hypertension undergoing orthopedic surgery of the lower limbs: a randomized controlled trial","volume":"23","author":"Q Xu","year":"2023","journal-title":"BMC Anesthesiol"},{"key":"pone.0330769.ref033","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2147\/DDDT.S359496","article-title":"Quality of Recovery After General Anesthesia with Remimazolam in Patients\u2019 Undergoing Urologic Surgery: A Randomized Controlled Trial Comparing Remimazolam with Propofol","volume":"16","author":"Y Mao","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"pone.0330769.ref034","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12871-023-01974-9","article-title":"Comparison of hemodynamics during induction of general anesthesia with remimazolam and target-controlled propofol in middle-aged and elderly patients: a single-center, randomized, controlled trial","volume":"23","author":"R Sekiguchi","year":"2023","journal-title":"BMC Anesthesiol"},{"key":"pone.0330769.ref035","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.2147\/DDDT.S375957","article-title":"Profile of Remimazolam in Anesthesiology: A Narrative Review of Clinical Research Progress","volume":"16","author":"M Wang","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"pone.0330769.ref036","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40264-023-01302-7","article-title":"Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update","volume":"46","author":"P Garc\u00eda-Abeijon","year":"2023","journal-title":"Drug Saf"},{"issue":"2","key":"pone.0330769.ref037","first-page":"97","article-title":"Disproportionality Analysis and Causal Inference in Drug Safety","volume":"39","author":"E Scosyrev","year":"2025","journal-title":"Pharmaceut Med"},{"issue":"1","key":"pone.0330769.ref038","doi-asserted-by":"crossref","first-page":"31239","DOI":"10.1038\/s41598-024-82582-6","article-title":"The effect of toluene sulfonic acid remimazolam on postoperative delirium in elderly patients undergoing painless bronchoscopy","volume":"14","author":"Y Shi","year":"2024","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T17:24:57Z","timestamp":1755883497000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330769"}},"subtitle":[],"editor":[{"given":"Anmar","family":"Al-Taie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330769","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}